Information Provided By: 
Fly News Breaks for September 11, 2018
MYGN
Sep 11, 2018 | 06:59 EDT
Barclays analyst Jack Meehan lowered his price target for Myriad Genetics to $25 and keeps a Underweight rating on the name. The analyst has new concerns with the Impact study for Myriad's GeneSight after performing additional diligence. He notes that Myriad is submitting the study to Medicare for expanded coverage for primary care physicians. Meehan says that if the Centers for Medicare & Medicaid Services shares some of the same concerns, it increases the chances of a more limited coverage outcome for Myriad.
News For MYGN From the Last 2 Days
There are no results for your query MYGN
